The Safety and Efficacy of HAIC+Tislelizumab+Regorafenib in Patients With Colorectal Liver Metastases

NCT05877001 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Liver Metastases

Interventions

DRUG: Tislelizumab
DRUG: Regorafenib
OTHER: HAIC

Sponsor

Peking University Cancer Hospital & Institute